Thread by @drprashantmish6

I like Jubilant life Sciences but I like it because of its Radiopharmaceuticals segment,I am just summarising what is it’s Radiopharma business( trying to keep it simple although topic is complicated)

Radiopharmaceuticals are pharmaceutical formulations that contain radioisotopes that are bound with the biological molecules that are targeted for the specific organs.
The molecules resulting from these formulations are used in
(a) Therapy ( Treatment)
(b) Diagnosis

These products are distributed through the radio pharmacies ( which is another jubilant business segment) that specifically dispense radioactive pharmaceutical products.( for normal medicine pharmacy and for Radiopharmaceuticals drugs Radiopharmacy)

Global Radiopharmaceuticals Market is expected to register a CAGR of 8.10% to reach USD 15,060.87 Million by 2025. The diagnostics segment is likely to hold a maximum market share of around 80% and rest is therapeutic.

The Global Radiopharmaceuticals Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The global radiopharmaceuticals market in the Americas is segmented into North America and Latin America. In this region, North America is expected to dominate the market.

Americas is expected to command the largest market share owing to the presence of a vast patient population suffering from chronic diseases like cancer, coronary disorders, and strokes, changing lifestyles and with increase in old age population

oncology is the segment which will witness a considerably high growth rate over others in the coming years. Advancements in oncology such as imaging and improved diagnosis methods will create several growth opportunities.

The increasing application of therapeutic ( treatment)radiopharmaceuticals in the treatment of cancers is also anticipated to drive the segment growth.

Global players in this business Lantheus Medical Imaging,
Cardinal Health
Norgine B.V.
Curium
Advanced Accelerator Applications (Novartis AG)
Bracco Diagnostic Inc.
Jubilant Life Sciences Limited
GE Healthcare (General Electric Company)
Bayer AG
Eli Lilly and Company

Jubilant continues to increase the range of product offerings in North America, while expanding into the Latin America, European and Asian markets through collaboration, contractual arrangements with partners and new distribution channels to drive growth

Different Products offering by Jubilant
Brain Imaging
• DTPA and Gluceptate Thyroid Therapy
• I-131 Iodine and HICON

Cardiac PET Imaging
• RUBY-FILL
Cardiac SPECT Imaging
• Sestamibi
Kidney Imaging
• DTPA and Gluceptate Functional Lung Imaging
• MAA and DTPA
Bone Imaging
• MDP
Leukocyte Labeling
• Exametazime

How it works small amounts are given to the patient. The radiopharmaceutical then passes through, or is taken up by, an organ of the body (which organ depends on what radiopharmaceutical is used and how it has been given).

Then the radioactivity is detected, and pictures are produced, by special imaging equipment. These pictures allow the nuclear medicine doctor to study how the organ is working and to detect cancer or tumors that may be present in the organ.

Some radiopharmaceuticals are used in larger amounts to treat certain kinds of cancer and other diseases. In those cases, the radioactive agent is taken up in the cancerous area and destroys the affected tissue.

How this therapy is excellent for example Drax Exametazime, which is currently approved in the United States, is a radiopharmaceutical used in nuclear medicine to help doctors locate infection in a patient when a source of the infection cannot be accurately identified

After giving injection of Drax Exametazine it’s radioactivity is detected in abdomen and doctor according to its radioactivity can detect in which organ infection is present.

With growing old population,growing incidence of cancer , heart and lung disease , growing range of Radiopharma and new uses along with growing Geography of Jubilant life Sciences will definitely help it’s Radiopharma business to grow in coming years .

@threadreaderapp unroll

For growth Jubilant is targeting new launch and FY21 they are planning to launch Ruby- Fill ( imagine for heart ) in Europe

Right now Jubilant is having 13 Radiopharma products in market and 8 products under development which will be launched in next 2-3 yrs .

navidea.com/news-media/pre…( this is for diagnostic help in Rheumatoid arthritis) read it for detail , another good product.